Analysis of Local Treatment-emergent Adverse Events in Patients With CIDP Treated With fSCIG During the ADVANCE-CIDP1 and Long-term ADVANCE-CIDP3 Trials (P7-9.001)

Ade Ajibade; Faisal Riaz; NEIL LAMARRE; Damion Nero; Kimberly Duff; E. Greco; Enrique García; Hakan Ay

doi:10.1212/wnl.0000000000217021

June 9, 2026Neurology

Analysis of Local Treatment-emergent Adverse Events in Patients With CIDP Treated With fSCIG During the ADVANCE-CIDP1 and Long-term ADVANCE-CIDP3 Trials (P7-9.001)

View Full Paper

Ask AI

Bookmark

Share

Key Points

The research aims to evaluate the incidence of local treatment-emergent adverse events associated with fSCIG in CIDP patients.
Data from the ADVANCE-CIDP1 and CIDP3 trials (NCT02549170/NCT02955355) was analyzed.
Participants received hyaluronidase-facilitated subcutaneous immunoglobulin treatment.
The analysis focused on local treatment-emergent adverse events.
Identified incidence rates of TEAEs in patients receiving fSCIG treatment.
Provided evidence of specific local adverse events related to the treatment.
Contributed to understanding the safety profile of fSCIG in CIDP patients.

Implication

Assesses adverse events in patients with CIDP treated with fSCIG, indicating safety concerns.

Abstract

To assess the incidence of local treatment-emergent adverse events (TEAEs) with hyaluronidase-facilitated subcutaneous immunoglobulin (fSCIG) during the ADVANCE-CIDP1/CIDP3 trials (NCT02549170/NCT02955355).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ajibade et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf393faef96ed7f0560e2 https://doi.org/10.1212/wnl.0000000000217021

View Full Paper

Ask AI

Bookmark

Share

Analysis of Local Treatment-emergent Adverse Events in Patients With CIDP Treated With fSCIG During the ADVANCE-CIDP1 and Long-term ADVANCE-CIDP3 Trials (P7-9.001)

Key Points

Implication

Abstract

Discussion

Cite This Study

Analysis of Local Treatment-emergent Adverse Events in Patients With CIDP Treated With fSCIG During the ADVANCE-CIDP1 and Long-term ADVANCE-CIDP3 Trials (P7-9.001)

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading